Sugemalimab is under clinical development by EQRx and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData, Phase II drugs for Natural Killer Cell Lymphomas have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sugemalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sugemalimab overview

Sugemalimab (Cejemly) is an recombinant human anti-PD-L1 monoclonal antibody. It is formulated as solution for intravenous route of administration. Cejemly in combination with pemetrexed and carboplatin is indicated as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations and in combination with paclitaxel and carboplatin as first-line treatment of patients with metastatic squamous NSCLC. Cejemly is indicated for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.

Sugemalimab (Cejemly) is under development for the treatment of solid tumors including endometrial cancer, cholangiocarcinoma, recurrent head and neck squamous cell carcinoma (HNSCC).

EQRx overview

EQRx is a biotechnology company that focuses on creating novel patent-protected medicines at lower prices. The company leverages advanced science and technology techniques focused on re-engineering the process of drug discovery and development of small molecule and biologic drugs for life threatening and chronic diseases treatments, with significant focus on cancer, immuno-inflammatory and genetic diseases. EQRx offers new medications less than the price of traditional pharmaceutical companies, and markets directly to payers and hospital systems instead of consumers. The company is funded by Google Ventures, ARCH Venture Partners LP, Andreessen Horowitz LLC, Casdin Capital LLC, Section 32, Nextech Venture Ltd and Arboretum Ventures LLC. EQRx is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Sugemalimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.